TORONTO--(EON: Enhanced Online News)--Medworxx Inc. (“Medworxx”) (TSXV:MWX), a leader in patient flow solutions, announced today the agreement with Greater East Midlands Commissioning Support Unit (GEM) to license Medworxx Patient Flow for their annual reviews delivered within their region covering a 4.5 million population and 13,000 beds in acute or community- based hospitals, or non- hospital environments. GEM will have access to the Medworxx Appropriate Length of Stay Audit Program capability in undertaking their reviews.
“With audit reviews licensed to GEM, there is the potential to sell full licenses for operational use in the future.”
Established in 2010, GEM is the NHS Clinical Support Unit (CSU) that supports and works on behalf of the 20 Clinical Commissioning Groups (CCGs) in the East Midlands area. These CCGs serve a population of over 4.500,000 and fund the provider trusts with over 9,000 medical, surgical and community beds and 4,000 mental health places. GEM will be using Medworxx Clinical Criteria to conduct reviews, snapshot audits and ongoing embedded reviews. Medworxx Patient Flow will provide GEM with the tools for demand capacity and planning to help ensure that, during the audit, all patients in the region are receiving the right care at the right time in the right place.
“GEM’s Utilisation Review (UR) has an established track record and unique level of experience in delivering a UR programme, and we’re excited to be supporting their programme to deliver its clients with further potential to enhance reporting,” said Dan Matlow, President and CEO at Medworxx. “With audit reviews licensed to GEM, there is the potential to sell full licenses for operational use in the future.”
GEM has signed on to a three year commitment with Medworxx, and will conduct a minimum of 11 reviews per annum to cover the inpatient and other NHS services in the East Midlands catchment area. GEM will be joining Medworxx UK clients’, The Royal Liverpool and Broadgreen University Hospitals and the South Tees NHS Foundation Trusts, using the robust Medworxx criteria to identify underlying reasons why there are conservable days, in real time.
Our success to date in the UK has been fuelled by path-finder organisations that recognise the value to the patient and the organisation of basing patient care transition decisions on rigorous objective criteria, rather than personal opinion, to identify & remove barriers preventing effective patient flow.
Medworxx delivers health information technology solutions to over 350 hospitals internationally; including Canada, United States and United Kingdom. Medworxx helps hospitals meet patient flow challenges, and requirements in compliance and education. Medworxx Clinical Criteria —flagship of Medworxx Patient Flow that includes electronic bed management and independent assessment components—currently serves over 33% of the acute- care beds in Canada, and approximately 2,000 beds in UK’s NHS. Founded in 2004, Medworxx Inc. is based in Toronto, ON, and publicly traded on the TSX Venture Exchange: MWX
GEM is an NHS service created by commissioners across the East Midlands to provide flexible, dedicated, specialist support. Since April 2010, GEM has worked alongside commissioners and providers who deliver health services to over 4.5 million people.
Their services include providing NHS organisations with online business intelligence and benchmarking to improve performance, help in strengthening contracts to reflect best practice in care delivery, procurement support, using evidence based tools to assess and improve frontline care, communicating healthcare trends and sharing knowledge and skills.
The statements made in this press release may contain forward-looking statements that may involve a number of risks and uncertainties. Actual events or results could differ materially from the company’s expectations and projections. The TSX Venture Exchange has not reviewed this press release and neither approved nor disapproved the information contained in this press release.